Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors
Grant Award Details
Grant Type:
Grant Number:
CLIN2-09439
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$6,653,266
Status:
Active
Grant Application Details
Application Title:
Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors
Public Abstract:
Therapeutic Candidate or Device
blood stem cells and T cells from organ transplant donors will be studied under this proposal to prevent rejection of kidney transplants
Indication
to withdraw immunosuppressant drugs from kidney transplant recipients
Therapeutic Mechanism
Injection of the donor blood stem cells into recipients will prevent recipient immune cells from rejecting the donor kidney transplant.
Unmet Medical Need
The proposed treatment eliminates the life long need of immunosuppressive drugs to prevent kidney transplant rejection. Immunosuppresive drugs increase the risks of cancer, infection, and heart disease.
Project Objective
Phase 1 trial completed
Major Proposed Activities
blood stem cells and T cells from organ transplant donors will be studied under this proposal to prevent rejection of kidney transplants
Indication
to withdraw immunosuppressant drugs from kidney transplant recipients
Therapeutic Mechanism
Injection of the donor blood stem cells into recipients will prevent recipient immune cells from rejecting the donor kidney transplant.
Unmet Medical Need
The proposed treatment eliminates the life long need of immunosuppressive drugs to prevent kidney transplant rejection. Immunosuppresive drugs increase the risks of cancer, infection, and heart disease.
Project Objective
Phase 1 trial completed
Major Proposed Activities
- Manufacture of the optimum donor cell product for injection into kidney transplant recipients
- Assess the clinical safety of the donor cell injection
- Assess the ability of the donor cell injection to eliminate the need for life long immunosuppressive drugs
Statement of Benefit to California:
The proposed research is designed to improve the health status of California citizens who have received kidney transplants. Transplant recipients currently need life long immunosuppressive drugs to prevent transplant rejection. Elimination of these drugs using donor blood stem cell injections will eliminate the need for these drugs and their attendant side effects and financial costs.
Publications
- Front Immunol (2022): Establishment of Chimerism and Organ Transplant Tolerance in Laboratory Animals: Safety and Efficacy of Adaptation to Humans. (PubMed: 35222384)
- Hum Immunol (2018): Macrochimerism and clinical transplant tolerance. (PubMed: 29330112)
- Sci Transl Med (2020): Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. (PubMed: 31996467)
